KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Gross Margin (2016 - 2025)

Historic Gross Margin for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to 42.84%.

  • Neogenomics' Gross Margin fell 17800.0% to 42.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 43.46%, marking a year-over-year decrease of 800.0%. This contributed to the annual value of 43.92% for FY2024, which is 25700.0% up from last year.
  • Neogenomics' Gross Margin amounted to 42.84% in Q3 2025, which was down 17800.0% from 42.61% recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Gross Margin peaked at 44.92% during Q4 2024, and registered a low of 32.63% during Q1 2022.
  • Its 5-year average for Gross Margin is 40.57%, with a median of 41.01% in 2023.
  • Examining YoY changes over the last 5 years, Neogenomics' Gross Margin showed a top increase of 113300bps in 2021 and a maximum decrease of -96000bps in 2021.
  • Over the past 5 years, Neogenomics' Gross Margin (Quarter) stood at 35.99% in 2021, then increased by 14bps to 40.97% in 2022, then increased by 6bps to 43.45% in 2023, then rose by 3bps to 44.92% in 2024, then dropped by -5bps to 42.84% in 2025.
  • Its Gross Margin stands at 42.84% for Q3 2025, versus 42.61% for Q2 2025 and 43.59% for Q1 2025.